Posted by Michael Wonder on 12 Jun 2018
The UK National Institute for Health and Care Excellence to undertake a partial review of the Iluvien reimbursement guidance allowing broader availability
11 June 2018 - More patients in England and Wales with chronic DME could benefit from low-dose corticosteroid intravitreal implant that lasts up to three years.
Alimera Sciences today announced that the United Kingdom National Institute for Health and Care Excellence will undertake a partial review and appraisal of Technology Assessment 301.
Currently reimbursement of Iluvien in England and Wales is only available for patients who have had their natural lens replaced with an artificial one (termed "pseudophakic"). Real-world data under the current recommendation has demonstrated not only cost-effectiveness, but also cost savings to the National Health Service when compared to alternative treatments.
